Yael Kopleman

Learn More
PURPOSE The miniature biodegradable implant siG12D-LODER™ was inserted into a tumor and released a siRNA drug against KRAS(G12D) along four months. This novel siRNA based drug was studied, in combination with chemotherapy, as targeted therapy for Locally Advanced Pancreatic Cancer (LAPC). METHODS An open-label Phase 1/2a study in the first-line setting of(More)
  • 1